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SHORT REPORT
Sporadic Creutzfeldt–Jakob disease with cerebellar
ataxia at onset in the UK
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Objective: To determine the frequency, in the UK, of sporadic
Creutzfeldt–Jakob Disease (sCJD) with a cerebellar ataxic
onset, and to describe the clinical features of the syndrome.
Methods: A retrospective review of autopsy-proved cases of
sCJD cases in the UK, 1990–2005, identifying those
presenting with cerebellar features without early cognitive
decline.
Results: 29 of 618 (5%) patients with sCJD had an isolated
cerebellar onset. Mean illness duration was 9 months.
Subsequently, 21 (72%) developed myoclonus and 23
(79%) developed pyramidal features. Magnetic resonance
imaging showed high signal in the basal ganglia in 11 of 14
(79%) patients. 7 of 15 (47%) patients were valine
homozygotic at prion protein gene (PRNP)-129. Only 8
(28%) cases were referred to the surveillance unit after death.
Conclusion: A better definition of sCJD presenting with an
isolated cerebellar syndrome might improve future case
recognition and contribute to the determination of its cause.
S
poradic Creutzfeldt–Jakob disease (sCJD) is an invari-
ably fatal neurodegenerative disease characterised typi-
cally by rapidly progressive dementia and a short
duration of illness. Most patients with sCJD present with
cognitive decline quickly followed by the development of a
variety of neurological symptoms, usually culminating in
akinetic mutism.1 The most common differential diagnoses
are Alzheimer’s disease and dementia with Lewy bodies.2 A
subgroup of patients with sCJD present with a virtually
isolated cerebellar syndrome,3 and in some, cognitive decline
may be delayed for weeks or even months. Although
cerebellar features are common in patients with sCJD (seen
in 19–47% of cases at symptom onset4 5 and in 42–86%
throughout the illness6 7), these largely accompany global
cognitive decline and often other neurological features. The
frequency of cases with a pure cerebellar onset is unclear, and
the clinical description of such cases has been largely limited
to case reports or as part of the phenotypic spectrum of
genetic8 or iatrogenic Creutzfeldt–Jakob disease (CJD).9 A
progressive, isolated cerebellar ataxia suggests several possi-
ble diagnoses (including inherited and metabolic disorders,
paraneoplastic syndromes and demyelinating disease).
Understandably, CJD is rarely the first consideration. This
study aimed to determine the frequency, of pathologically
proved cases of sCJD presenting with a virtually isolated
cerebellar syndrome in the UK and to describe the clinical
features and investigation results (including prion protein
gene (PRNP)-129 analysis).
METHOD
A retrospective case-note review was undertaken of all
pathologically proved cases of sCJD referred to the UK
National CJD Surveillance Unit (NCJDSU) between January
1990 and October 2005, to identify those with a virtually
isolated cerebellar syndrome at onset (defined as individuals
presenting with features of cerebellar dysfunction in the
absence of any documented memory loss or confusion for at
least 1 month from symptom onset). Patients were visited
when alive, where possible, by an NCJDSU neurologist; a
comprehensive clinical history was obtained from the
patient’s relatives and a full neurological examination was
carried out. If not visited when alive, the patient’s relatives
were then visited later to confirm details of the history.
Details from hospital records and general practitioner notes
were requested for each case along with copies of relevant
investigations (electroencephalogram (EEG), brain magnetic
resonance imaging (MRI) and cerebrospinal fluid (CSF)
analysis). Cases were selected blinded to PRNP-129 genotype.
RESULTS
Twenty nine of 618 (5%) patients with sCJD presented with a
cerebellar syndrome in the absence of any documented
cognitive impairment for at least the first month of their
illness. Of these, 20 (69%) were men. The mean age at
symptom onset was 63 years (median 61 years, range 48–
76 years). The mean duration of illness was 9 months
(median 7 months, range 2–36 months). All but one were
aged >50 years at disease onset. PRNP gene mutation
analysis was carried out in 17 of 29 (59%) cases; no
disease-related mutations were identified. None of the
patients without genetic analysis had a family history of
dementia in a first-degree relative.
Unsteadiness or poor coordination were early features in
all patients. The first documented symptoms were gait
unsteadiness in 20 (69%) patients, dizziness in 6 (21%), poor
coordination in 2 (7%) and dysarthria in 1 (3%). In a few
patients, associated minor neurological symptoms were
observed at presentation: 3 of 29 (10%) patients had sensory
symptoms (burning sensations in the left upper and lower
limbs in one and paraesthesia across the lumbar region in
two); 2 of 29 (7%) patients had visual symptoms at onset
(one with blurred vision and the other with double vision).
Two others had non-specific accompanying symptoms at
onset: one with headache and the other with excessive
tiredness. There were no reports of excessive weight loss at
onset to suggest a paraneoplastic cause.
Documented cognitive decline was delayed in all by at least
1 month (mean 3 months; range 1–9 months). Other neuro-
logical features became evident with disease progression
(table 1).
Abbreviations: CJD, Creutzfeldt–Jakob disease; CSF, cerebrospinal
fluid; EEG, electroencephalogram; MRI, magnetic resonance imaging;
NCJDSU, National CJD Surveillance Unit; PRNP, Prion protein gene;




CSF 14-3-3 protein was analysed in 15 of 29 cases, and was
positive in 12 (80%) and negative in 3 (20%). Brain MRI was
available in 14 of 29 cases. In all, 11 (79%) scans showed high
signal in the head of the caudate nucleus and putamen, and
three were normal. None of the scans displayed high signal in
the cerebellum. MRI scans were carried out at a mean age of
7.7 months (range 1–34 months) after symptom onset. The
first recorded positive scan was carried out 3 months after
symptom onset and scans were recorded as negative as late as
12 months from onset. All patients had at least one EEG, but
characteristic features of sCJD were found in only 3 of 29
(10%) patients. PRNP-129 analysis was carried out in 17
patients, 3 (18%) of whom were methionine homozygotic
(MM), 6 (35%) were methionine–valine heterozygotic (MV)
and 8 (47%) were valine homozygotic (VV). Prion protein
glycotype analysis carried out in 13 (45%) patients showed
that one patient was MM1, one was MV1, three were MV2A,
one was VV1 and seven were VV2A.
A total of 21 (72%) patients were referred to the NCJDSU
when alive. In five others, referral was made after death but
before the results of autopsy were known. In the remaining
three the diagnosis was made only at autopsy. When alive,
two of these patients were thought to have paraneoplastic
disease, and in the third no diagnosis was made.
DISCUSSION
sCJD may present with an isolated, or virtually isolated,
cerebellar ataxia, which is usually referred to as the
Brownell–Oppenheimer variant.3 Cerebellar features are
common in sCJD7 and often occur early.4 In this study, we
specifically selected those cases that present with an isolated
or virtually isolated cerebellar syndrome and, in particular,
those without cognitive impairment at presentation. The
frequency of this type of presentation has previously been
uncertain. We have shown that over a 15-year period of CJD
surveillance in the UK, 29 patients have presented in this
way, representing 5% of all cases of sCJD. Approximately one
third of all patients with sCJD present with memory loss,
with the next most common presentation being that of ataxia
(although frequently in combination with cognitive decline).2
In the early stages, the differential diagnosis is wide and
sCJD is often not considered until dementia supervenes. A
paraneoplastic cerebellar syndrome is a relatively frequent
differential diagnosis. Paraneoplastic disease may manifest as
a sensory peripheral neuropathy,10 and sensory symptoms
were present, at some stage, in one third of our cases. Genetic
prion disease may present with a cerebellar syndrome. Twelve
of our patients did not undergo genetic testing and none had
a family history of CJD. No iatrogenic exposure to prion
disease was detected in any of the patients.
The duration of illness in this group was longer than that
typical for sCJD (overall mean illness duration 4 months).11
Our patients often exhibited a striking delay in cognitive
decline; patients may have insight into the diagnosis if it is
made early enough. Ultimately, however, all patients
exhibited a rapidly progressive dementia, often with myoclo-
nus.
More men than women (M:F approximately 2:1) were
observed as presenting with virtually isolated cerebellar
features, but our sample size is too small to establish a true
male predominance.
Investigations including CSF 14-3-3 and MRI were useful
in this context, each displaying a diagnostic sensitivity of
about 80%, but it must be noted that a positive 14-3-3 result
may be found in other conditions, including paraneoplastic
disease.12 The EEG was characteristic for sCJD in only 3 of 29
(10%) tested cases. This may relate in part to EEG timing as
one third of patients were still walking, albeit unsteadily, at
the time of the last EEG recording, whereas the three patients
with typical EEG findings were bed-bound with myoclonus at
the time of the recording. Characteristic EEG changes are
more likely in the later stages of sCJD.13 To the best of our
knowledge, high signal in the basal ganglia structures on
MRI has not been reported in paraneoplastic disease.
sCJD has a considerable degree of clinicopathological
heterogeneity, particularly (although not only) in relation
to presenting features.14 Reported determinants or associa-
tions of disease phenotype include age at onset, PRNP-129
genotype and PrP protein type. Early and dominant cerebellar
features, in the absence of familial disease, have been
associated with valine homozygosity at PRNP-129.15 In the
UK, 11% of all patients with sCJD are PRNP-129 valine
homozygotic,16 whereas 47% of our patients were of this
genotype. Patients with a pure cerebellar onset are not
particularly young (a median age of 61 years compared with
67 years for sCJD as a whole in the UK).16
The reason for the variation in the clinical presentation of
sCJD is uncertain. The cause of sCJD is unknown. The
dominant theory is that it results from a stochastic PrP
protein change or a somatic PRNP mutation,17 and, if so,
different onsets may simply reflect random initial sites of
disease.
Among the cerebellar onset group, a relatively high
number of patients (28%) were not referred to the NCDJSU
when alive. For complete surveillance, the need to encourage
referral of unusual cases should be emphasised.
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